Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
way to go to recoup my original investment but am now showing profit on surrent trades. Long may this recovery continue.... AVIA Bid: 8.25p Offer: 9p Change: 1.375
AVIA Bid: 7.25p Offer: 8p Change: 1.250
current to the post
topping up by 70k shares. BUYING 70,000 AVIA HEAL @ £0.110852 Action Buy Quantity 70,000 Shares Symbol AVIA Firm Price £0.110852 Premium Hell of a premium...
Not KN confused myself!
Well done - you seem to have the same % as Vychan Properties Ltd Have dropped a few k here but capitalised the losses and have a tidy sum reinvested. When we hit .08p I'll be in profit and might even have to use earlier losses to offset!!
shall I turn off the lights???.................
s.996 Powers of the court under this Part (1) If the court is satisfied that a petition under this Part is well founded, it may make such order as it thinks fit for giving relief in respect of the matters complained of. (2) Without prejudice to the generality of subsection (1), the court’s order may— (a) regulate the conduct of the company’s affairs in the future; (b) require the company— (i) to refrain from doing or continuing an act complained of, or (ii) to do an act that the petitioner has complained it has omitted to do; (c) authorise civil proceedings to be brought in the name and on behalf of the company by such person or persons and on such terms as the court may direct; (d) require the company not to make any, or any specified, alterations in its articles without the leave of the court; (e) provide for the purchase of the shares of any members of the company by other members or by the company itself and, in the case of a purchase by the company itself, the reduction of the company’s capital accordingly.
From: HCL Investors <notohcloffer@yahoo.com> Subject: No to HCL Offer Campaign - Update To: Date: Tuesday, 16 April, 2013, 10:03 Dear All, This morning various RNS releases were issued by HCL. This included: 1. Former director Kate Bleasdale has given notice of a claim pursuant to section 994 of the Companies Act 2006. In UK law this is a provision to claim for unfair prejudice in a statutory form that can be brought by aggrieved shareholders against their company. Kate Bleasdale asserts that HCL should purchase her current shareholding at a price of £1.12 per share being the share price immediately prior to its suspension in January 2011. The extract of the provision and court remedies have been appended. 2. Healthcare Australia's Managing Director Andy McRae has stepped down from his position on the Board of HCL with immediate effect. Further, we are in contact with the Takeover Panel regarding the lack of disclosure of the financial performance and position as at 31 December 2012 in the formal offer RNS release issued on 11 April 2013. Given a quarter has passed post-yearend it is reasonable to expect this information to be disclosed to all shareholders particularly since it is likely this information would have been key to the Board's decision-making. With Regards, No to HCL Offer Campaign notoHCLoffer@yahoo.com Note the below is provided for information purposes only. No responsibility will be taken for providing this information. It is based on information from sources believed to be reliable, but the accuracy cannot be guaranteed. No reliance should be placed on this information. Legal advice should be sought before considering any action. s 994 Petition by company member (1) A member of a company may apply to the court by petition for an order under this Part on the ground— (a) that the company’s affairs are being or have been conducted in a manner that is unfairly prejudicial to the interests of members generally or of some part of its members (including at least himself), or (b) that an actual or proposed act or omission of the company (including an act or omission on its behalf) is or would be so prejudicial. (2) The provisions of this Part apply to a person who is not a member of a company but to whom shares in the company have been transferred or transmitted by operation of law as they apply to a member of a company. (3) In this section, and so far as applicable for the purposes of this section in the other provisions of this Part, “company” means— (a) a company within the meaning of this Act, or (b) a company that is not such a company but is a statutory water company within the meaning of the Statutory Water Companies Act 1991 (c 58). s.996 Powers of the court under this Part (1) If the court is satisfied that a petition under this Part is well founded, it may make such order as it thinks fit for giving relief in
Healthcare Locums Directorate Change RNS Number : 4019C Healthcare Locums PLC 16 April 2013  Healthcare Locums plc ("HCL" or the "Company") Directorate Change Andy McRae has decided to leave Healthcare Australia (HCA) in his capacity as Managing Director, Australia to return to the UK and has stepped down from the Healthcare Locums Group Board (HCL Plc) with immediate effect. Andy has led HCA through a number of significant business changes during difficult market conditions and the Board would like to thank Andy for his contribution to the Group and wish him well for the future as he seeks his next challenge beyond HCL Plc. Jason Cartwright will be joining HCA on 17 April 2013 as CEO, Australia reporting to Group Chief Executive, Stephen Burke. Jason joins Healthcare Australia with over 22 years experience in the recruitment industry, many of these leading Volume Recruitment businesses as a Sales and Business Development Director and then more recently as a Group General Manager. Jason was latterly at Randstad PTY Ltd where he was Group Director with divisional responsibility for Healthcare and other recruitment specialisations across Australia and New Zealand.
thanks opti - think I'll hang for a while have a feeling that there is still mileage left in holding to at least the 28 day period ends and then review
Dear All, This is a short email to the shareholder action group to communicate our acknowledgement of the Offer promulgated today for HCL. At this stage we strongly believe that shareholders should NOT dispose of their shareholding. However since you are free to do so if you so choose, please notify us if you have disposed of your shares either partially or in full since we will need to update our information accordingly. We continue to encourage you to direct other shareholders that have not already done so to register their interest by email to notoHCLoffer@yahoo.com. We will be in contact in due course. With Regards, No to HCL Offer Campaign
when's the deadline for acceptance and payment?
Bglobal PLC Agreement with GnERGY RNS Number : 7498Z Bglobal PLC 12 March 2013  12 March 2013 BGLOBAL PLC ("Bglobal" or the "Company" or the "Group") Bglobal announces agreement with GnERGY Bglobal plc (AIM:BGBL), the leading provider of smart energy solutions and services to the UK energy market, today announced that it has signed a deal with GnERGY Ltd. This deal will enable GnERGY to become a dual fuel energy supplier, and will be the seventh company to take advantage of the 'Supplier in a Box' ™ solution that Bglobal's subsidiary Utiligroup delivers to new market entrants. The agreement is another example of Bglobal's strategy to facilitate entry to the UK energy market, and cements its position as the market leader in this field. Utiligroup, as part of Bglobal, enables businesses of all sizes to enter the highly competitive energy sector by offering expertise, support and access to licenses and software. The 'Supplier in a Box'™ package will minimize the time it takes GnERGY to be operational in the market, as Bglobal offers it an array of logistical and technical support through Utiligroup. This support includes access to Utiligroup's full range of energy software, implementation services and consultancy from the 'Client Solutions' team, operational managed services and a license through the pre-accredited supply company 'Lumen Energy Supply Ltd'. Tikendra Dewan at GnERGY commented: "We believe that we have a unique proposition in the UK energy market with our plans to directly serve our community in this way. As such, we required a partner that understands our unique needs and has the skills and experience to help us achieve our goals. We found that Utiligroup were the only company in the market that could deliver not only the pre-accredited energy supply company that will help us begin operations more quickly, but also the industry-leading software and services that will enable us to meet the needs of our community customer base." Tim Jackson-Smith, CEO of Bglobal plccommented: "We are delighted to have been selected by GnERGY to support their entry into the utilities sector. They have a unique, community-focused business model and we are pleased to help them achieve their objectives in the coming years. GnERGY has become the 7th new entrant to implement our 'Supplier in a Box'™ solution, and we continue to see enduring interest in the proposition from parties interested in becoming domestic or SME energy suppliers."
KeywordCompanyEPIC/TIDMSEDOL/ISINNews Price Announcements Fundamentals News Article RSS Bglobal PLC (BGBL) Add to Alerts list Print Mail a friend Wednesday 06 March, 2013 Bglobal PLC Holding(s) in Company RNS Number : 3544Z Bglobal PLC 06 March 2013 BGLOBAL PLC ("Bglobal" or the "Company" ) Holding in Company Bglobal plc (AIM: BGBL), (the "Company") announces that it has received notification on 5 March 2013 that Lazard Frères Gestion, as asset manager of French UCITS, is interested in 5,618,000 ordinary shares of the Company representing 5.28% of the voting rights of the Company.
Adv Medical Soln Grp Final Results RNS Number : 3229Z Advanced Medical Solutions Grp PLC 06 March 2013  6 March 2013 Advanced Medical Solutions Group plc ("AMS" or the "Group") Preliminary Results for the year ended 31 December 2012 Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the global medical technology company, today announces its unaudited preliminary results for the year ended 31 December 2012. Financial Highlights: • Group revenue up 53% to £52.6 million (2011: £34.4 million), representing growth of 57% on a constant currency basis¹ ○ Underlying like-for-like Group revenue on a constant currency basis (excluding RESORBA®) up by 3% to £35.1 million (2011: £34.4 million) • Adjusted2 operating margin up 520 bps to 24.3% (2011: 19.1%) • Adjusted2 profit before tax up 85% to £12.1 million (2011: £6.6 million) ○ Profit before tax up 135% to £10.8 million (2011: £4.6 million) • Adjusted2 fully diluted earnings per share up 24% to 5.30p (2011: 4.28p) ○ Fully diluted earnings per share up 53% to 4.66p (2011: 3.04p) • Operating cash flow before exceptional items3 of £13.4 million (2011: £6.7 million) • Net debt reduced to £5.5 million (2011: £13.4 million) ○ £3.6 million of original €25 million loan to acquire RESORBA® has been repaid ahead of schedule • Proposed final dividend of 0.35p per share, making a total dividend for the year of 0.52p (2011: 0.45p), a 16% increase compared with the prior year Business Highlights: • ActivHeal® continues its excellent progress in the NHS, with a 29% increase in revenues • Silver alginate revenues increased by 22% • RESORBA® integration completed ○ LiquiBand® sales in Germany via RESORBA® increased by 15% ○ Successful contract award to supply NHS with sutures, haemostats as well as tissue adhesives from October 2012 • In the US, LiquiBand® market share by volume increased strongly to 13% (H1 2012: 10%) in the alternate site segment, although it declined to 4% (H1 2012: 6%) in the hospital segment ○ New growth strategy launched for LiquiBand® in the US • New trilaminate foam range launched into the EU and to the NHS • Reorganisation of the Group complete to deliver growth
Access Intelligence CHANGE OF ADVISER RNS Number : 3230Z Access Intelligence PLC 06 March 2013  6 March 2013 AIM: ACC Access Intelligence plc ("Access Intelligence" or the "Company") Appointment of Nomad and Sole Broker Access Intelligence is pleased to announce the appointment of Merchant Securities Limited as Nominated Adviser and Sole Broker to the Company with immediate effect.
Important Notice Investec Bank plc, who is authorised and regulated in the UK by the Financial Services Authority, is acting for HCL and no-one else in connection with the possible offer and will not regard any other person as a client in relation to the possible offer and will not be responsible to anyone other than HCL for providing the protections afforded to its clients or for providing advice in relation to the possible offer or any matters referred to in this announcement.
Healthcare Locums Extension of deadline RNS Number : 3103Z Healthcare Locums PLC 06 March 2013  NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF THAT JURISDICTION. THIS ANNOUNCEMENT IS NOT AN ANNOUNCEMENT OF A FIRM INTENTION TO MAKE AN OFFER UNDER RULE 2.7 OF THE CITY CODE ON TAKEOVERS AND MERGERS (THE "CODE") AND THERE CAN BE NO CERTAINTY THAT AN OFFER WILL BE MADE, NOR AS TO THE TERMS ON WHICH ANY OFFER WILL BE MADE. Healthcare Locums plc ("HCL" or the "Company") Extension of deadline in accordance with Rule 2.6 (c) of the Takeover Code 6 March 2013 On 6 February 2013 HCL announced it had received, in connection with its seeking an injection of further capital into the Company, an indicative joint proposal ("Indicative Proposal") from Toscafund Asset Management LLP ("Toscafund") and Ares Capital Europe Limited ("ACE") to acquire all the outstanding ordinary shares of the Company not already owned by them and their concert parties at a price in cash of at least 0.54 pence per share. Toscafund and ACE had until 5.00 p.m. on 6 March 2013 to either announce a firm intention to make an offer for the Company in accordance with Rule 2.7 of the Code or announce that it does not intend to make an offer, in which case the announcement will be treated as a statement to which Rule 2.8 of the Code applies. The Company has today, with the consent of the Panel, agreed to an extension of this deadline under Rule 2.6(c) of the Code until 5.00pm on 3 April 2013. This revised deadline will only be extended with the consent of the Panel in accordance with Rule 2.6(c) of the Code. The Board of HCL has seen an indicative proposal from Toscafund and ACE that demonstrates that they are continuing to work towards making a formal offer under Rule 2.7 of the Code and the provision of additional capital to the Company to allow it to pursue its strategy. In order to finalise their proposal, Toscafund and ACE need an extension to the timetable to reach agreement with HCL's lending banks.
7.00AM 05 MARCH 2013 ACCESS INTELLIGENCE PLC ("Access Intelligence" or "the Group") PRELIMINARY RESULTS FOR THE YEAR ENDED 30 NOVEMBER 2012 Access Intelligence Plc (AIM: ACC), a leading supplier of Software-as-a-Service (SaaS) solutions for the full life cycle management of a company's governance, risk and compliance, announces its unaudited results for the year ended 30 November 2012 . Highlights * Turnover from continuing activities increased by 11% to £8,053,000 (2011: £7,223,000) * Contracted not yet invoiced revenue up 101% to £5,453,000 (2011: £2,713,000) * Recurring revenue up 16% to £5,562,000 (2011: £4,807,000) at 69% of sales (2011: 66%) * Adjusted EBITDA on continuing activities down 49% to £368,000 (2011:£720,000)* * Loss after tax on continuing activities was £114,000 (2011: loss £91,000) * Loss after tax on continuing and discontinued activities was £114k (2011: profit £2,101,000) * Loss per share on continuing and discontinued operations 0.05p (2011: profit 0.84p) * Cash balance of £2,772,000 (2011: £4,162,000). * Total technology spend of £1,929k (2011:£639k) of which £706,000 (2011:£314,000) was capitalised * Proposed final dividend of 0.05p per share (2011: 0.2p) payable on 26 April 2013. *The adjusted EBITDA has been arrived at before development cost impairment, share based payments and exceptional costs. Michael Jackson, Executive Chairman, commented: - 2012 has seen strategic investment in both the Company and its solutions. We have already started to see the early signs of return on this investment, with a significant increase in revenues contracted not yet invoiced and an increase in long term shareholder value with a growing recurring revenue base. Our strategy continues to evolve and the synergies and interoperability between our products continues to grow, with customers recognising considerable benefits from utilising our combined suite of brands